Cite
A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors.
MLA
Thomas, Jacob S., et al. “A Phase I Study of Intravenous Fenretinide (4-HPR) for Patients with Malignant Solid Tumors.” Cancer Chemotherapy and Pharmacology, vol. 87, no. 4, Apr. 2021, pp. 525–32. EBSCOhost, https://doi.org/10.1007/s00280-020-04224-8.
APA
Thomas, J. S., El-Khoueiry, A. B., Maurer, B. J., Groshen, S., Pinski, J. K., Cobos, E., Gandara, D. R., Lenz, H. J., Kang, M. H., Reynolds, C. P., & Newman, E. M. (2021). A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemotherapy and Pharmacology, 87(4), 525–532. https://doi.org/10.1007/s00280-020-04224-8
Chicago
Thomas, Jacob S, Anthony B El-Khoueiry, Barry J Maurer, Susan Groshen, Jacek K Pinski, Everardo Cobos, David R Gandara, et al. 2021. “A Phase I Study of Intravenous Fenretinide (4-HPR) for Patients with Malignant Solid Tumors.” Cancer Chemotherapy and Pharmacology 87 (4): 525–32. doi:10.1007/s00280-020-04224-8.